Cureworth Drugs & Intermediates Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 09-12-2024
- Paid Up Capital ₹ 4.00 M
as on 09-12-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.05 Cr
as on 09-12-2024
- Satisfied Charges ₹ 10.84 Cr
as on 09-12-2024
- Revenue -41.68%
(FY 2022)
- Profit -69.03%
(FY 2022)
- Ebitda -45.71%
(FY 2022)
- Net Worth 6.23%
(FY 2022)
- Total Assets -4.88%
(FY 2022)
About Cureworth Drugs & Intermediates
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹13.05 Cr. The company has closed loans amounting to ₹10.84 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramchandra Nishad and Anjana Nishad serve as directors at the Company.
- CIN/LLPIN
U24232MH2010PTC204157
- Company No.
204157
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Cureworth Drugs & Intermediates Private Limited offer?
Cureworth Drugs & Intermediates Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API, API Intermediate, Common Disease Medicines, Allopathic Cough Syrup, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Cureworth Drugs & Intermediates?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramchandra Nishad  | Director | 14-Jun-2010 | Current |
| Anjana Nishad | Director | 15-Jun-2010 | Current |
Financial Performance of Cureworth Drugs & Intermediates.
Cureworth Drugs & Intermediates Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 41.68% decrease. The company also saw a substantial fall in profitability, with a 69.03% decrease in profit. The company's net worth moved up by a moderate rise of 6.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cureworth Drugs & Intermediates?
In 2022, Cureworth Drugs & Intermediates had a public holding of 6.35%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Anuj Engineers (I) Private LimitedActive 38 years 11 monthsRamchandra Nishad and Anjana Nishad are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Mar 2023 | ₹6.45 Cr | Open |
Hdfc Bank Limited Creation Date: 24 Mar 2023 | ₹6.60 Cr | Open |
Bank Of India Creation Date: 28 Jun 2021 | ₹2.50 Cr | Satisfied |
How Many Employees Work at Cureworth Drugs & Intermediates?
Cureworth Drugs & Intermediates has a workforce of 39 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cureworth Drugs & Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cureworth Drugs & Intermediates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
